FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation By Ogkologos - October 30, 2025 68 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR FDA Approves Fruquintinib for Patients with Refractory Metastatic Colorectal Cancer November 20, 2023 Mom Unknowingly Has Cancer For 3 Years After Doctor Keeps Telling... March 21, 2019 Reflections from the World Cancer Congress November 30, 2022 New targeted treatment for early breast cancer could reduce risk of... July 21, 2022 Load more HOT NEWS For Women Returning from Breast Cancer Treatment, Work Often Changes Involuntarily Hundreds Of Thousands Of Peruvian Women Were Forcibly Sterilized, And Now... Taking on DNA repair to tackle cancer Maintenance Rucaparib for Platinum-Sensitive Pancreatic Adenocarcinoma with HRD-Associated Mutations
